SCHEMBL764122

SCHEMBL764122

C[C@H]1CC(O)CN1C(=O)OC(C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.49
CHRM1 P11229 1/20 0.49
CHRM3 P20309 1/20 0.49
CYP1A2 P05177 1/20 0.45
POLB P06746 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C19 P33261 1/20 0.45
NR1H2 P55055 1/20 0.41
TSHR P16473 1/20 0.41
ATM Q13315 1/20 0.37
HSD11B1 P28845 1/20 0.36
USP2 O75604 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
DPP4 P27487 2/20 0.36
DPP8 Q6V1X1 2/20 0.36
DPP9 Q86TI2 2/20 0.36
HSD17B10 Q99714 1/20 0.35
GPR119 Q8TDV5 1/20 0.35
PIK3CD O00329 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3247661 1.00 CHRM2 (0.49) CHRM2CHRM1CHRM3CYP1A2POLB
SCHEMBL764147 1.00 CHRM2 (0.49) CHRM2CHRM1CHRM3CYP1A2POLB
SCHEMBL2202251 1.00 CHRM2 (0.49) CHRM2CHRM1CHRM3CYP1A2POLB
SCHEMBL13079208 1.00 CHRM2 (0.49) CHRM2CHRM1CHRM3CYP1A2POLB
SCHEMBL2202801 1.00 CHRM2 (0.49) CHRM2CHRM1CHRM3CYP1A2POLB
SCHEMBL4881170 1.00 CHRM2 (0.49) CHRM2CHRM1CHRM3CYP1A2POLB
SCHEMBL376321 1.00 CHRM2 (0.49) CHRM2CHRM1CHRM3CYP1A2POLB
Pyrazine SCHEMBL31128788 0.91 CYP1A2 (0.43) CHRM2CHRM1CHRM3CYP1A2POLB
SCHEMBL23564630 0.86 CHRM2 (0.45) CHRM2CHRM1CHRM3CYP1A2POLB
SCHEMBL16853219 0.86 CHRM2 (0.45) CHRM2CHRM1CHRM3CYP1A2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12275728-B2 O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors BIOGEN MA INC. (US) 2025-04-15 US disclosed
US-12180205-B2 O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors BIOGEN MA INC. (US) 2024-12-31 US disclosed
US-20240308995-A1 O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS BIOGEN MA INC. 2024-09-19 US disclosed
CN-117940425-A HER2 mutation inhibitors 阿雷生物药品公司 2024-04-26 CN disclosed
WO-2021086966-A1 SPIROCYCLIC O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS BIOGEN MA INC. (US) 2021-05-06 WO disclosed
WO-2020163193-A1 BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS BIOGEN MA INC. (US) 2020-08-13 WO disclosed
EP-3212642-B1 AMIDE SUBSTITUTED THIAZOLES AS MODULATORS OF RORGAMMAT JANSSEN PHARMACEUTICA NV (BE) 2019-10-30 EP disclosed
US-9845319-B2 Amide substituted thiazoles as modulators of RORyt Janssen Pharmaceutiuca NV (BE) 2017-12-19 US disclosed
US-20160122335-A1 AMIDE SUBSTITUTED THIAZOLES AS MODULATORS OF RORyt JANSSEN PHARMACEUTICA NV (US) 2016-05-05 US disclosed
EP-2678338-B1 PYRAZOLO[1,5-A]PYRIDINES AS TRK INHIBITORS NOVARTIS AG (CH) 2015-09-09 EP disclosed
US-9102671-B2 Compounds and compositions as TRK inhibitors NOVARTIS AG (CH) 2015-08-11 US disclosed
EP-1565436-B1 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS INCYTE CORP (US) 2012-04-25 EP disclosed
EP-2431357-A2 3-Aminopyrrolidine Derivatives as Modulators of Chemokine Receptors Incyte Corporation (US) 2012-03-21 EP disclosed
US-20110251168-A1 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS INCYTE CORPORATION 2011-10-13 US disclosed
US-7985730-B2 3-aminopyrrolidine derivatives as modulators of chemokine receptors INCYTE CORPORATION (US) 2011-07-26 US disclosed
US-7834021-B2 3-aminopyrrolidine derivatives as modulators of chemokine receptors INCYTE CORPORATION (US) 2010-11-16 US disclosed
US-20090247474-A1 3-Aminopyrrolidine Derivatives As Modulators Of Chemokine Receptors INCYTE CORPORATION 2009-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160122335-A1 AMIDE SUBSTITUTED THIAZOLES AS MODULATORS OF RORyt RORC, RORA, RORB CHRM2 627/4885CHRM1 422/4885CHRM3 1434/4885
US-12180205-B2 O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors MGAT3, MAN2A1, ENGASE CHRM2 1025/4885CHRM1 1292/4885CHRM3 1649/4885
US-20240308995-A1 O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS MGAT3, MAN2A1, ENGASE CHRM2 1025/4885CHRM1 1292/4885CHRM3 1649/4885
US-20090247474-A1 3-Aminopyrrolidine Derivatives As Modulators Of Chemokine Receptors CCR2, CXCR3, CCR5 CHRM2 69/4885CHRM1 63/4885CHRM3 161/4885
US-20110251168-A1 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS CCR2, CXCR3, CCR5 CHRM2 69/4885CHRM1 63/4885CHRM3 161/4885
US-12275728-B2 O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors MGAT3, MAN2A1, ENGASE CHRM2 1025/4885CHRM1 1292/4885CHRM3 1649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.